Probing the Mechanism of Action of Bis(phenolato) Amine (ONO Donor Set) Titanium(IV) Anticancer Agents
Mustapha Musa, Mohammed Abid, Tracey D. Bradshaw, David J. Boocock, Clare Coveney, Stephen P. Argent, Simon Woodward
Abstract
High Resolution Image Download MS PowerPoint Slide The need for anticancer therapies that overcome metallodrug resistance while minimizing adverse toxicities is targeted, herein, using titanium coordination complexes. Octahedral titanium(IV) trans, mer -[Ti{R 1 N(CH 2 –2-MeO-4-R 1 -C 6 H 2 ) 2 } 2 ] [R 1 = Et, allyl, n -Pr, CHO, F, CH 2 (morpholino), the latter from the formyl derivative; R 2 = Me, Et; not all combinations] are attained from Mannich reactions of commercial 2-methoxyphenols (27–74% overall yield, 2 steps). These crystalline (four X-ray structures) Ti(IV)-complexes are active against MCF-7, HCT-116, HT-29, PANC-1, and MDA-MB-468 cancer cell lines (GI 50 = 0.5–38 μM). Their activity and cancer selectivity (vs nontumor MRC-5 cells) typically exceeds that of cisplatin (up to 16-fold). Proteomic analysis (in MCF-7) supported by other studies (G2/M cell cycle arrest, ROS generation, γH2AX production, caspase activation, annexin positivity, western blot, and kinase screens in MCF-7 and HCT-116) suggest apoptosis elicited by more than one mechanism of action. Comparison of these data to the modes of action proposed for salan Ti(IV) complexes is made.